This includes upfront payments and revenues to be recognised in the current year and through to 2017.
In its latest trading update, the company says the potential for these contracts was highlighted in the interim results and they ensure that, despite increasing investment in both healthcare technology development and commercial infrastructure in the USA, the outturn for this year should be similar to 2014 and provide a strong contracted revenue base for the next fiscal year. Accordingly 2016 is expected to be a year of material growth as the Company continues to make significant commercial and technological advances.
Commenting on the results Steven Powell, Chief Operating Officer, said: "We are pleased to have made significant progress in our pharmaceutical clinical trials business and these contracts provide a strong foundation for continued growth in 2016."
*******
Enquiries:
Cambridge Cognition Holdings plc
Steven Powell, Chief Operating Officer
Tel: 01223 810 700
Nick Walters, Chief Financial Officer
finnCap Ltd (Nomad and Broker)
Tel: 020 7220 0500
Geoff Nash/Simon Hicks
(Corporate Finance)
Malar Velaigam
(Corporate Broking)
Walbrook PR Ltd
Tel: 020 7933 8780 or [email protected]
Paul McManus
Mob: 07980 541 893
Lianne Cawthorne
Mob: 07584 391 303
________________________________________________
Cambridge Cognition ends the year on a high note
24 November 2015
Cambridge Cognition Holdings plc, a specialist in the development and marketing of computerised tests for detection and monitoring of neuropsychological disorders, is pleased to announce that it has made significant progress with its commercial operations and expects to end the year with three new major pharmaceutical clinical trial contracts totalling US$4.5m.